Sanofi invests in JHL Biotech, gets exclusive rights to rituximab biosimilar
Executive Summary
JHL Biotech Inc. granted Sanofi exclusive rights to sell JHL1101, its biosimilar to Rituxan (rituximab), in China once approved. The deal could later be expanded to include additional territories.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice